PLX Technology Inc news

  
Showing stories 1 - 10 of about 71   

Articles published

PLXT 0.0000
price chart
Broadcom Nearing Deal to Settle Lawsuit Over 2014 PLX Technology Takeover
Broadcom Ltd. is nearing a deal to settle a shareholder lawsuit accusing it of underpaying in a 2014 takeover of PLX Technology Inc., according to people familiar with the matter, a case that also leveled allegations of conflicts of interest at PLX's ...
US Department of Defense to Conduct Studies of Pluristem's PLX-R18 in a New ...
16, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that a pilot study of the company's PLX-R18 cell therapy will be initiated by the U.S ...
Ex-JPMorgan Analyst Tipped Pals To Tech Deals, Jury Told
As a result of their purchasing securities on the basis of insider information, the three men earned more than $600,000 in illicit profits when the acquisitions of the companies, PLX Technologies Inc. and ExactTarget Inc., were publicly announced ...
BRIEF-Rita O'Connor appointed CFO of PLx Pharma
SAN FRANCISCO, June 30 A well-known Silicon Valley investor, Dave McClure, has been demoted within the firm he co-founded, 500 Startups, the latest fallout from revelations of mistreatment of women in the technology industry. An internal investigation ...
Delaware Court of Chancery schedule, April 24 to April 28
PLX Technology Inc. 2 p.m. Dover, oral argument before Vice Chancellor Slights, Canal View Investment Co. v. Beacon Canal View.
Hot On The Charts: Protalix BioTherapeutics, Inc. (PLX), LiNiu Technology ...
Protalix BioTherapeutics, Inc. (NYSE:PLX) traded at an unexpectedly low level on 6/30/2017 when the stock experienced a 1.52% gain to a closing price of $0.84.
Polaryx Therapeutics Receives Orphan Drug Designation From the US FDA for PLX ...
"Granting PLX-200 the Orphan Drug Designation is one of the company's significant development milestones," says Dr.
PLx Pharma Inc. Announces Pricing of Registered Direct Offering
The Company intends to use the net proceeds from this offering, together with current cash resources, to advance Aspertec 325 mg to market-readiness; to obtain supplemental regulatory approval of Aspertec 81 mg; to fund the technology transfer and the ...
Protalix Biotherapeutics Inc - Receive News & Ratings Daily
Protalix Biotherapeutics logo Renaissance Technologies LLC raised its stake in Protalix Biotherapeutics Inc (NYSEMKT:PLX) by 302.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund ...
Protalix Biotherapeutics Inc (NYSEMKT:PLX) Downgraded by Zacks Investment ...  BNB Daily (blog)
PLx Pharma Inc. Reports Second Quarter 2017 Results
10, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together ...